Ceryvyn Therapeutics Ltd
OPT
Helyezés a részvények között
#31847
Opthea Limited is an Australian clinical-stage biopharmaceutical company... Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage. The company's leading asset, OPT 302, is a soluble form of VEGFR3 currently undergoing clinical trials. This novel therapy aims to treat wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is distinguished as a first-in-class VEGF-C/D inhibitor, intended to be used in conjunction with VEGF-A inhibitors for the treatment of wet AMD and various other retinal diseases. Originally incorporated in 1984 as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015 and is headquartered in South Yarra, Australia.
Részvényárfolyam
$0.00846342
Utolsó szinkronizálás: 2026-07-27
Piaci kapitalizáció
$11.27M
Változás (1 nap)
0.00%
Változás (1 év)
-99.75%
Ország
AU
Kereskedés Ceryvyn Therapeutics Ltd (OPT)
Kategória
Healthcare
Ceryvyn Therapeutics Ltd (OPT) P/B aránya
P/B arány ekkor: October 2026 TTM: -2.59
Ceryvyn Therapeutics Ltd legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi könyv szerinti árfolyam aránya (P/B, TTM) -2.59. 2024 végén ez az arány -2.90 volt.
P/B arány története a(z) Ceryvyn Therapeutics Ltd esetén 2000 és 2026 között
P/B arány az év végén
| Év | P/B arány | Változtassa meg |
|---|---|---|
| 2026 (TTM) | -2.59 | -29.13% |
| 2025 | -3.65 | 25.83% |
| 2024 | -2.90 | -85.14% |
| 2023 | -19.55 | -581.67% |
| 2022 | 4.06 | 114.11% |
| 2021 | 1.90 | -80.02% |
| 2020 | 9.49 | 100.78% |
| 2019 | 4.72 | 47.97% |
| 2018 | 3.19 | 24.94% |
| 2017 | 2.56 | -54.83% |
| 2016 | 5.66 | 328.12% |
| 2015 | 1.32 | 19.54% |
| 2014 | 1.11 | 20.15% |
| 2013 | 0.92 | 1.79% |
| 2012 | 0.90 | -26.82% |
| 2011 | 1.24 | 37.49% |
| 2010 | 0.90 | -19.70% |
| 2009 | 1.12 | 23.30% |
| 2008 | 0.91 | -28.98% |
| 2007 | 1.28 | 17.34% |
| 2006 | 1.09 | -43.38% |
| 2005 | 1.92 | -39.58% |
| 2004 | 3.18 | 10.89% |
| 2003 | 2.87 | -4.95% |
| 2002 | 3.02 | -37.54% |
| 2001 | 4.83 | -54.32% |
| 2000 | 10.58 | 0.00% |
P/B arány hasonló vállalatoknál vagy versenytársaknál
| Vállalat | P/B arány | P/B arány különbség | Ország |
|---|---|---|---|
| 6.251 | -341.64% |
US
|
|
| 13.2547 | -612.38% |
US
|
|
| 4.208 | -262.67% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -338.99% |
NL
|
